The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.

Oncotarget · 2016 · PMC5342757 · PMID 27776352

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Our study whilst borderline significant showed that D994D had an impact on OS in trastuzumab treated HER2-positive BC patients.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.